[go: up one dir, main page]

KR910009700A - 3-피페리디닐-1,2-벤즈이속사졸 - Google Patents

3-피페리디닐-1,2-벤즈이속사졸 Download PDF

Info

Publication number
KR910009700A
KR910009700A KR1019890016114A KR890016114A KR910009700A KR 910009700 A KR910009700 A KR 910009700A KR 1019890016114 A KR1019890016114 A KR 1019890016114A KR 890016114 A KR890016114 A KR 890016114A KR 910009700 A KR910009700 A KR 910009700A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
general formula
acid addition
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019890016114A
Other languages
English (en)
Other versions
KR0146053B1 (ko
Inventor
게리두스 마리아 쟈안센 코르비루우스
귀리엘무스 크냅스 알폰수스
에드몬트 죠셉핀 케니스 루도
반덴베르크 쟈안
Original Assignee
구스타프 반 리이트
쟈안센 파아마슈우티카 엔.부이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 구스타프 반 리이트, 쟈안센 파아마슈우티카 엔.부이 filed Critical 구스타프 반 리이트
Publication of KR910009700A publication Critical patent/KR910009700A/ko
Application granted granted Critical
Publication of KR0146053B1 publication Critical patent/KR0146053B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

내용 없음

Description

3-피페리디닐-1,2-벤즈이속사졸
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 일반식(Ⅰ)의 화합물 그 산부가염 또는 그 입체 이성체.
    위의 일반식에서, AIk는 C1-4알칸리일이고, R1은 수소, C1-4알킬 또는 할로이고, R2는 C1-4알킬이고, R3는 히드록시 또는 R4-C(=O)O이고, R4는 C1-19알킬이다.
  2. 제1항에 있어서, R3이 6,7,8,9-테트라히드로-2-C1-4알킬-4H-피리도[1,2-a]피리미딘-4-온 부분의 9위치에 치환된 일반식(I)의 화합물, 그 산부가염 또는 그 입체 이성체.
  3. 제2항에 있어서, AIk가 에탄리일, R1이 할로이고, R2가 메틸인 일반식(I)의 화합물, 그 산부가염 또는 그 입체이성체.
  4. 제1항에 있어서, 3-[2-[4-(6-플루오로-1,2-벤즈이속사졸-3-일)-1-피페리디닐]에틸-6,7,8,9-테트라히드로-9-히드록시-2-메틸-4H-피리도[1,2-a]피리미딘-4-온, 그 산부가염 또는 그 거울상체(enatiomer)인 화합물.
  5. 유효성분으로 일반식(I)의 화합물, 그 산부가염 또는 그 입체이성체를 항정신병성 치료효과량과 함께 불활성 담체로 조성된 항정신병성 약제조성물.
    위의 일반식에서, AIk는 C1-4알칸리일이고, R1은 수소, C1-4알킬 또는 할로이고, R2는 C1-4알킬이고, R3는 히드록시 또는 R4-C(=O)O이고, R4는 C1-19알킬이다.
  6. 제5항에 있어서, R3이 6,7,8,9-테트라히드로-2-C1-4알킬-4H-피리도[1,2-a]피리미딘-4-온 부분의 9위치에 치환된 약제조성물.
  7. 제5항에 있어서, 3-[2-[4-(6-플루오로-1,2-벤즈이속사졸-3-일)-1-피페리디닐]에틸]-6,7,8,9-테트라히드로-9-히드록시-2-메틸-4H-피리도[1,2-a]피리미딘-4-온, 그 산부가염 또는 그 거울상체인 약제 조성물.
  8. 일반식(I)의 화합물, 그 산부가염 또는 그 입체이성체를 항정신병성 치료효과량 온형동물에 투여하여, 정신병성 질환에 걸린 온혈동물을 치료하는 방법.
    위의 일반식에서, AIk는 C1-4알칸리일이고, R1은 수소, C1-4알킬 또는 할로이고, R2는 C1-4알킬이고, R3는 히드록시 또는 R4-C(=O)O이고, R4는 C1-19알킬이다.
  9. 제8항에 있어서, R3이 6,7,8,9-테트라히드로-2-C1-4알킬-4H-피리도[1,2-a]피리미딘-4-온 부분의 9위치에 치환된 일반식(I)의 화합물, 그 산부가염 또는 입체이성체를 항정신병성 치료효과량 온형동물에 투여하여, 정신병성 질환에 걸린 온형동물을 치료하는 방법.
  10. a)일반식(Ⅱ)의 3-피페리디닐-1,2-벤즈이속사졸을 불활성 용매중에서 승온하에 일반식(Ⅲ)의 화합물로 N-알킬화하거나, b)일반식(Ⅳ)의 욕심을 반응불활성 용매중에서 염기와 함께 승온하에 폐환 반응시키거나, c)일반식(V)의 활성옥심을 불활성 용매중에서 염기와 함께 승온하에 폐환 반응시키거나, d)일반식(I-a)의 화합물을 일반식(Ⅵ)의 카르복시산 또는 그 반응성 유도체를 불활성 용매 중에서 O-아실화하거나, e)일반식(VⅡ)의 아미딘을 일반식(VⅢ)의 -디카르보닐 중간화합물로 불활성용매중에서 승온하에 폐환 반응시키거나, f)일반식(IX)의 화합물을 일반식(X)의 에나민을 불활성 용매중에서 승온하에 폐환 반응시키거나, g)일반식(I-a)의 화합물의 라세미체 혼합물을, 분해제에 의해 부분입체 이성질체염 또는 화합물의 혼합물로 전환시키기고, 부분입체이성체 또는 화합물의 혼합물을 분리한후, 분리한 부분입체 이성체염 또는 화합물을 일반식(I-a)의 화합물의 상응하는 거울상체로 전환시켜 일반식(I)의 화합물, 그 산부가염 또는 그 입체이성체를 제조하는 방법.
    위의 일반식에서, AIk는 C1-4알칸디일이고, R1은 수소, C1-4알킬 또는 할로이고, R2는 C1-4알킬이고, R3는 히드록시 또는 R4-C(=O)O이고, R4는 C1-19알킬이고, Y는 반응성 이탈기이고, L은 산의 잔기이고, R5는 반응성 이탈기이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890016114A 1988-11-07 1989-11-07 3-피페리디닐-1,2-벤즈이속사졸 Expired - Lifetime KR0146053B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26785788A 1988-11-07 1988-11-07
US267857 1988-11-07
US267,857 1988-11-07

Publications (2)

Publication Number Publication Date
KR910009700A true KR910009700A (ko) 1991-06-28
KR0146053B1 KR0146053B1 (ko) 1998-08-17

Family

ID=23020416

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890016114A Expired - Lifetime KR0146053B1 (ko) 1988-11-07 1989-11-07 3-피페리디닐-1,2-벤즈이속사졸

Country Status (21)

Country Link
EP (1) EP0368388B1 (ko)
JP (1) JP2758045B2 (ko)
KR (1) KR0146053B1 (ko)
AT (1) ATE122349T1 (ko)
AU (1) AU614437B2 (ko)
CA (1) CA2000786C (ko)
CL (1) CL43432B (ko)
CY (2) CY1926A (ko)
DE (2) DE68922577T2 (ko)
DK (1) DK169923B1 (ko)
ES (1) ES2075036T3 (ko)
FI (1) FI92201C (ko)
HK (1) HK131696A (ko)
IE (1) IE66370B1 (ko)
IL (1) IL92208A0 (ko)
LU (1) LU91362I2 (ko)
NL (1) NL300298I2 (ko)
NO (2) NO173015C (ko)
NZ (1) NZ231062A (ko)
PT (1) PT92206B (ko)
ZA (1) ZA898436B (ko)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
NZ245260A (en) * 1991-11-27 1995-06-27 Novo Nordisk As Piperidine derivatives, preparation and pharmaceutical compositions thereof
US5378714A (en) * 1991-11-27 1995-01-03 Novo Nordisk A/S Antipsychotic piperidine derivatives
ES2050069B1 (es) * 1992-07-10 1994-12-16 Vita Invest Sa Procedimiento para la obtencion de 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-il)piperidino)etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido(1,2-a) pirimidin-4-ona.
DK60593D0 (da) * 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
DK60793D0 (da) * 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
RU2178695C2 (ru) * 1993-11-19 2002-01-27 Жансен Фармасетика Н.В. Микрокапсулы, содержащие рисперидон, фармацевтическая композиция и способы их получения
ES2137486T3 (es) * 1993-11-23 1999-12-16 Janssen Pharmaceutica Nv Derivados de 9-hidroxi-pirido(1,2-a)pirimidin-4-ona-eter.
ES2085234B1 (es) * 1994-02-24 1997-01-16 Vita Invest Sa Agente activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ES2141671B1 (es) * 1997-12-26 2001-01-01 Vita Invest Sa Compuesto pirimidinico activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
AU3984899A (en) 1998-05-18 1999-12-06 Sepracor, Inc. (-)-hydroxyrisperidone compositions and methods
WO1999059590A1 (en) * 1998-05-18 1999-11-25 Sepracor Inc. (+)-hydroxyrisperidone compositions and methods
US6342488B1 (en) 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
ES2197801B1 (es) * 2002-03-05 2005-03-16 Ferrer Internacional,S.A Procedimiento de obtencion de la 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il) piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a ) pirimidin-4-ona.
KR20040025224A (ko) * 2002-09-18 2004-03-24 주식회사 대웅 2-(2-메틸-4-옥소-6,7,8,9-테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘-3-일)아세트알데히드 및 그 제조방법
WO2004043923A1 (en) 2002-11-13 2004-05-27 Synthon B.V. Process for making risperidone and intermediates therefor
US7723518B2 (en) 2004-09-09 2010-05-25 Janssen Pharmaceutica N.V. Preparation of 9-hydroxy-3-(2-hydroxyethyl)-2-methyl-4H-pyrido[1,2-A]pyrimidin-4-one
US20070197591A1 (en) 2005-12-12 2007-08-23 Sandra Boom Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
EP2133351A3 (en) * 2006-08-14 2010-01-13 Teva Pharmaceutical Industries Ltd. Crystal form of 9-hydroxy-risperidone (paliperidone)
JP2009524685A (ja) * 2006-08-14 2009-07-02 テバ ファーマシューティカル インダストリーズ リミティド ９−ヒドロキシ−リスペリドン（パリペリドン）の結晶型
EP2133352A3 (en) * 2006-08-14 2010-01-13 Teva Pharmaceutical Industries Ltd. Crystal form of 9-hydroxy-risperidone (paliperidone)
KR20090079189A (ko) * 2006-08-23 2009-07-21 테바 파마슈티컬 인더스트리즈 리미티드 Ｃｍｈｔｐ 및 이의 중간체의 합성 방법
US7820816B2 (en) 2006-08-23 2010-10-26 Teva Pharmaceutical Industries Ltd. Process for the synthesis of CMHTP and intermediates thereof
US8071767B2 (en) 2007-01-08 2011-12-06 Actavis Group Ptc Ehf Process for preparation of 9-hydroxy-3-(2-chloroethyl)-2-methyl-4H-pyrido[1,2-A]pyrimidin-4-one hydrochloride
DK2154138T3 (en) * 2007-04-19 2015-11-02 Youxin Li Novel compounds for the treatment of psychotic disorders, methods of preparation and uses thereof
WO2009010988A1 (en) * 2007-07-19 2009-01-22 Natco Pharma Limited An improved, industrially viable process for the preparation of high purity paliperidone
US20090036470A1 (en) * 2007-07-27 2009-02-05 Jiri Bartl Paliperidone derivatives
WO2009045489A2 (en) * 2007-10-03 2009-04-09 Teva Pharmaceutical Industries Ltd. Process for the synthesis of cmhtp, a paliperidone intermediate
NZ584370A (en) 2007-10-09 2011-04-29 Cipla Ltd Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes
US7977480B2 (en) 2007-12-10 2011-07-12 Synthon Bv Synthesis of paliperidone
NZ586930A (en) * 2008-02-05 2012-06-29 Watson Pharma Private Ltd An improved process for preparation of paliperidone
EP2285804A4 (en) * 2008-04-21 2011-09-14 Glenmark Generics Ltd METHOD FOR MANUFACTURING PALIPERIDONE INTERMEDIATES
EP2303877B1 (en) 2008-05-29 2017-02-15 Inke, S.A. Process to prepare paliperidone and intermediates thereof
US8481729B2 (en) 2008-06-16 2013-07-09 Msn Laboratories Limited Processes for the preparation of paliperidone
EP2318405A2 (en) * 2008-07-11 2011-05-11 Synthon B.V. Paliperidone ketone
US20100010218A1 (en) * 2008-07-11 2010-01-14 Jiri Bartl Synthesis of paliperidone
SI22856A (sl) * 2008-07-31 2010-02-26 Krka, Tovarna Zdravil, D.D., Novo Mesto Proces za pripravo paliperidona
EP2161019A1 (en) 2008-09-05 2010-03-10 KRKA, D.D., Novo Mesto Prolonged release multiparticulate pharmaceutical composition comprising paliperidone
EP2199293A1 (en) 2008-12-22 2010-06-23 Chemo Ibérica, S.A. One-step process for preparing paliperidone and its oxalate salt
EP2202234A1 (en) 2008-12-24 2010-06-30 Laboratorios Lesvi, S.L. Purification of paliperidone
SI2275423T1 (sl) 2009-07-13 2012-06-29 Krka D.D., Novo Mesto Postopek za sintezo paliperidona
WO2011018246A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Controlled release paliperidone composition
EP2343296A1 (en) 2009-12-01 2011-07-13 Chemo Ibérica, S.A. A process for the purification of paliperidone
WO2011074017A1 (en) * 2009-12-17 2011-06-23 Alkem Laboratories Ltd. A novel process for the preparation of paliperidone
US8088594B2 (en) * 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2012035554A1 (en) * 2010-09-14 2012-03-22 Megafine Pharma (P) Ltd. An improved process for the preparation of highly pure paliperidone
BR112013012062B1 (pt) 2010-11-15 2020-06-02 Agenebio, Inc Composto derivado da piridazina ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso do composto
CN102153552B (zh) * 2011-03-01 2012-08-22 吉林大学 两种帕潘立酮药物共晶及其制备方法
CN102206210B (zh) * 2011-04-01 2014-07-02 常州市第四制药厂有限公司 一种6-氟-3-(4-哌啶基)-1，2-苯并异噁唑盐酸盐的生产方法
HK1215170A1 (zh) 2012-11-14 2016-08-19 The Johns Hopkins University 治療精神分裂症的方法和組合物
CA2934553C (en) 2013-12-20 2023-10-31 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MA42624A (fr) 2015-06-19 2021-04-28 Agenebio Inc Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2019162746A1 (en) * 2018-02-21 2019-08-29 Zenvision Pharma Llp Novel derivatives of paliperidone and process for the preparation thereof
US11414425B2 (en) 2018-06-19 2022-08-16 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
IL319072A (en) 2022-08-19 2025-04-01 Agenebio Inc History of Benzazepine, Compositions and Methods for Treating Cognitive Impairment
CN116003404B (zh) * 2022-12-14 2024-10-01 杭州同舟生物技术有限公司 一种利培酮人工半抗原、人工抗原及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342870A (en) * 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

Also Published As

Publication number Publication date
FI895261A0 (fi) 1989-11-06
ES2075036T3 (es) 1995-10-01
NL300298I1 (nl) 2007-12-03
NO173015B (no) 1993-07-05
NO894411L (no) 1990-05-08
JP2758045B2 (ja) 1998-05-25
IL92208A0 (en) 1990-07-26
CY2007025I2 (el) 2009-11-04
FI92201C (fi) 1994-10-10
NO173015C (no) 1993-10-13
DK551989D0 (da) 1989-11-06
DE122007000081I2 (de) 2010-01-28
DK169923B1 (da) 1995-04-03
DE68922577D1 (de) 1995-06-14
CY2007025I1 (el) 2009-11-04
AU614437B2 (en) 1991-08-29
EP0368388B1 (en) 1995-05-10
DE68922577T2 (de) 1995-09-28
HK131696A (en) 1996-07-26
CL43432B (es) 2005-06-03
CA2000786C (en) 1999-01-26
EP0368388A2 (en) 1990-05-16
PT92206B (pt) 1995-07-06
CA2000786A1 (en) 1990-05-07
EP0368388A3 (en) 1991-07-17
IE66370B1 (en) 1995-12-27
KR0146053B1 (ko) 1998-08-17
NL300298I2 (nl) 2008-03-03
PT92206A (pt) 1990-05-31
NO894411D0 (no) 1989-11-06
JPH02191276A (ja) 1990-07-27
AU4443689A (en) 1990-05-10
NO2007017I1 (no) 2008-01-14
LU91362I2 (fr) 2007-11-12
IE893564L (en) 1990-05-07
DK551989A (da) 1990-05-08
DE122007000081I1 (de) 2008-02-28
CY1926A (en) 1989-10-30
FI92201B (fi) 1994-06-30
NZ231062A (en) 1991-09-25
NO2007017I2 (no) 2010-01-25
ATE122349T1 (de) 1995-05-15
ZA898436B (en) 1991-07-31

Similar Documents

Publication Publication Date Title
KR910009700A (ko) 3-피페리디닐-1,2-벤즈이속사졸
KR910018380A (ko) 신규 2,9-이치환된-4H-피리도[1,2-a]피리미딘-4-온
KR100794184B1 (ko) 디펩티딜 펩티데이즈-ｉｖ(ｄｐｐ-ｉｖ) 저해용 신규화합물, 그것의 제조방법 및 그것을 활성성분으로서함유하는 약제 조성물
RU2100357C1 (ru) Гетероариламины или их фармацевтически приемлемые соли и фармацевтическая композиция на их основе
EP0789571A1 (en) Cyclic amidine analogs as inhibitors of nitric oxide synthase
HRP960004A2 (en) 2,8-disubstituted quinazolinones
MXPA04008939A (es) Compuestos de quizolina utiles en terapia.
KR910016744A (ko) N-(4-피페리디닐)(디하이드로벤조푸란 또는 디하이드로-2h-벤조피란)카르복스아미드 유도체
WO2004002957A1 (en) Novel tetrahydropyridine derivatives as renin inhibitors
DE69433148T2 (de) Tricyclische kondensierte heterocyclische Verbindungen zur Behandlung von seniler Demenz
KR900700483A (ko) 푸로[3,4-c] 피리딘 에난티오미의 입체특이적 제조방법, 이와같이 제조된 화합물 및 그의 제약 조성물
GB9011469D0 (en) Chemical process
HUT70051A (en) Novel tricyclic-cyclic amines as cholinesterase inhibitors, pharmaceutical compositions containing them and process for preparing them
IE65712B1 (en) Isoxazole-beta-carboline derivatives
US5098904A (en) Cerebral function enhancing pyrimidinyl derivatives
CA2119755A1 (fr) Derives de benzonaphtyridine-1,8 et compositions antimicrobiennes
EP3969458A1 (en) Chemical compounds
RU2010794C1 (ru) Производные циклического амида или их фармакологически приемлемая соль, обладающая антиацетилхолинэстеродной активностью
IL107001A (en) History of acridinamino and pharmaceutical preparations containing them
KR900004588B1 (ko) 치환된 헥사히드로 아릴퀴놀리진 및 그의 제조방법
IE902956A1 (en) Pyrido [3,4-b] [1,4]benzoxazepines, a process for their¹preparation and their use as medicaments
EP0197318B1 (en) Benzo[C]-1,5-naphthyridines, a process and intermediates for their preparation and their use as medicaments
GB1596357A (en) Propanolamine derivatives
US4882332A (en) Immune suppression method employing arly-substituted naphthyridine and pyridopyrazine derivatives
EP0015786B1 (fr) Imidazo et pyrimido-pyrido-indoles, leur préparation et médicaments les contenant

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19891107

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19941031

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19891107

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19971030

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19980226

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19980507

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19980507

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20010502

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20020502

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20030424

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20040423

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20050422

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20060502

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20070424

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20080425

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20090424

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20100427

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20110502

Start annual number: 14

End annual number: 14

PR1001 Payment of annual fee

Payment date: 20120423

Start annual number: 15

End annual number: 15

FPAY Annual fee payment

Payment date: 20130419

Year of fee payment: 16

PR1001 Payment of annual fee

Payment date: 20130419

Start annual number: 16

End annual number: 16

FPAY Annual fee payment

Payment date: 20140421

Year of fee payment: 17

PR1001 Payment of annual fee

Payment date: 20140421

Start annual number: 17

End annual number: 17

FPAY Annual fee payment

Payment date: 20150417

Year of fee payment: 18

PR1001 Payment of annual fee

Payment date: 20150417

Start annual number: 18

End annual number: 18

FPAY Annual fee payment

Payment date: 20160419

Year of fee payment: 19

PR1001 Payment of annual fee

Payment date: 20160419

Start annual number: 19

End annual number: 19

EXPY Expiration of term
PC1801 Expiration of term